Thursday, September 29, 2016 12:07:08 PM
http://www.reuters.com/article/idUSFWN1C50HP?type=companyNews
Recent PTCT News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/18/2024 10:35:59 AM
- CHMP Maintains Negative Opinion on Translarna™ Reexamination • PR Newswire (US) • 10/18/2024 10:30:00 AM
- PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results • PR Newswire (US) • 10/14/2024 08:30:00 PM
- PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program • PR Newswire (US) • 10/08/2024 12:00:00 PM
- PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients • PR Newswire (US) • 10/01/2024 01:00:00 PM
- FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program • PR Newswire (US) • 09/26/2024 12:00:00 PM
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 09/12/2024 08:30:00 PM
- PTC Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 08/28/2024 08:30:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/27/2024 08:45:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:35:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:31 PM
- PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results • PR Newswire (US) • 08/08/2024 08:01:00 PM
- PTC Therapeutics Announces Sepiapterin NDA Submission to FDA • PR Newswire (US) • 07/30/2024 12:00:00 PM
- PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results • PR Newswire (US) • 07/25/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 09:20:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 07:14:16 PM
- CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review • PR Newswire (US) • 06/28/2024 10:00:00 AM
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 06/21/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:55:18 AM
- Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients • PR Newswire (US) • 06/20/2024 10:30:00 AM
- PTC Therapeutics to Participate at Upcoming Investor Conference • PR Newswire (US) • 05/29/2024 12:00:00 PM
- PTC Therapeutics Announces Validation of Sepiapterin European MAA • PR Newswire (US) • 05/28/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 09:20:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2024 02:12:33 PM
- PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation • PR Newswire (US) • 05/20/2024 04:20:00 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM